SEVERE CASES OF SEASONAL INFLUENZA IN RUSSIA IN 2015 - 2016 AND 2016 - 2017

Cover Page


Cite item

Full Text

Abstract

Aim. Evaluation of seroprevalence of antibodies to influenza A and В viruses and analysis of specimens from severe or fatal influenza cases in Russia in 2015 - 2016 and 2016 - 2017 flu seasons. Materials and methods. Determination of antibody titer in human serum samples in hemagglutination inhibition assay with reference antigens. Isolation of influenza viruses from nasopharyngeal swabs and autopsy material in cell culture. Characterization ofisolated strains. Results. In 2016, compared to 2015, the proportion of serum samples, containing antibodies to influenza viruses A(H 1N1 pdm09) and A(H3N2), increased. During the 2015-2016 season, elevated number of severe and fatal cases of influenza were registered. The majority of circulated strains belonged to the new clade 6B.1 of A(HlNippdm09 viruses. 1% of analyzed isolates carried H275Y amino acid substitution in neuraminidase and were resistant to oseltamivir. In the 2016 - 2017 season, there were less severe cases of influenza. The most prevalent were influenza viruses A(H3N2) and B/Victoria. Isolated H3N2 viruses belonged to the 3C.2a subclade and B/Victoria isolates were from the 1A genetic group. All tested strains were susceptible to neuraminidase inhibitors. Conclusions. Flu seasons 2015 - 2016 and 2016 - 2017 differed in intensity of influenza activity and in the dominant influenza A virus subtype. Immunization with vaccine, comprising new HlNlpdm09-component, is crucial for prophylaxis of influenza infection with viruses from 6B. 1 subclade in the next season. Neuraminidase inhibitors are recommended for influenza treatment.

About the authors

S. V. Svyatchenko

State Research Center of Virology and Biotechnology «Vector»

Author for correspondence.
Email: noemail@neicon.ru
Russian Federation

A. G. Durymanov

State Research Center of Virology and Biotechnology «Vector»

Email: noemail@neicon.ru
Russian Federation

I. M. Susloparov

State Research Center of Virology and Biotechnology «Vector»

Email: noemail@neicon.ru
Russian Federation

N. P. Kolosova

State Research Center of Virology and Biotechnology «Vector»

Email: noemail@neicon.ru
Russian Federation

N. I. Goncharova

State Research Center of Virology and Biotechnology «Vector»

Email: noemail@neicon.ru
Russian Federation

O. V. Petrova

State Research Center of Virology and Biotechnology «Vector»

Email: noemail@neicon.ru
Russian Federation

A. V. Epanchintseva

State Research Center of Virology and Biotechnology «Vector»

Email: noemail@neicon.ru
Russian Federation

A. V. Maksyutova

State Research Center of Virology and Biotechnology «Vector»

Email: noemail@neicon.ru
Russian Federation

K. S. Kondik

State Research Center of Virology and Biotechnology «Vector»

Email: noemail@neicon.ru
Russian Federation

O. K. Slaboda

State Research Center of Virology and Biotechnology «Vector»

Email: noemail@neicon.ru
Russian Federation

E. V. Ivanova

Centre of Hygiene and Epidemiology in Novosibirsk Region

Email: noemail@neicon.ru
Russian Federation

V. N. Mikheev

State Research Center of Virology and Biotechnology «Vector»

Email: noemail@neicon.ru
Russian Federation

A. B. Ryzhikov

State Research Center of Virology and Biotechnology «Vector»

Email: noemail@neicon.ru
Russian Federation

T. N. Ilicheva

State Research Center of Virology and Biotechnology «Vector»

Email: noemail@neicon.ru
Russian Federation

References

  1. Роспотребнадзор. О завершении эпидемического сезона по гриппу и ОРВИ 2015-2016. URL: http:,// rospotrebnadzor.ra/about/info/news/ news_details.php? ELEMENT_ID=5995.
  2. Роспотребнадзор. О ситуации по заболеваемости гриппом и ОРВИ за 49 неделю (05.12.2016-11.12.2016) и ходом иммунизации населения. URL: http://ww.rospotreb-nadzor.ra/abot//info/news/news_details.php?ELEMENT_ID=7513.
  3. European Centre for Disease Prevention and Control. Influenza virus characterisation, summary Europe, March 2016. Stockholm: ECDC, 2016.
  4. Flannery B., Chung J.R., Thaker S.N. et al. Interim estimates of 2016-17 seasonal influenza vaccine effectiveness, United States, February 2017. MMWR Morb. Mortal. Wkly. Rep. 2017, 66(6): 167-171.
  5. Katz J., Hancock K., Veguilla V. et al. Serum cross-reactive antibody response to a novel influenza A (H IN 1) virus after vaccination with seasonal influenza vaccine. MMWR Morb. Mortal. Wkly. Rep. 2009, 58 (19): 521-524.
  6. Kissling E., Rondy M., I-MOVE/I-MOVE+ study team. Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe. Euro Surveill. 2017, 22 (7): 30464.
  7. Standard operating procedure WHO-025. Fluorometric neuraminidase inhibition assay. URL: http://www.nisn.org/documents/A.Hurt_Protocol_for_NA_fluorescence/pdf.
  8. WHO. Recommended composition ofinfluenza virus vaccines for use in the 2017-2018 northern hemisphere influenza season. Wkly Epidemiol. Rec. 2017,92 (11): 117-128.
  9. World Health Organization surveillance network: Manual for the laboratory diagnosis and virological surveillance of influenza. Geneva: WHO Press, 2011.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2018 Svyatchenko S.V., Durymanov A.G., Susloparov I.M., Kolosova N.P., Goncharova N.I., Petrova O.V., Epanchintseva A.V., Maksyutova A.V., Kondik K.S., Slaboda O.K., Ivanova E.V., Mikheev V.N., Ryzhikov A.B., Ilicheva T.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС77-75442 от 01.04.2019 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies